ASCO 2026 | SYNERGY: nenocorilant and nivolumab in advanced solid malignancies
Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, comments on the rationale and design of the Phase Ib/II SYNERGY trial (NCT07276373) of nenocorilant, a selective glucocorticoid receptor antagonist, with nivolumab in patients with advanced solid malignancies. The study examines how glucocorticoid receptor antagonism may enhance or restore sensitivity to anti-PD-(L)1 therapy, with primary objectives focusing on safety, tolerability, and determining the optimal dosing regimen. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
